JP2024508334A5 - - Google Patents
Info
- Publication number
- JP2024508334A5 JP2024508334A5 JP2023553354A JP2023553354A JP2024508334A5 JP 2024508334 A5 JP2024508334 A5 JP 2024508334A5 JP 2023553354 A JP2023553354 A JP 2023553354A JP 2023553354 A JP2023553354 A JP 2023553354A JP 2024508334 A5 JP2024508334 A5 JP 2024508334A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- composition according
- lomitapide
- approximately
- period
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163155960P | 2021-03-03 | 2021-03-03 | |
| US63/155,960 | 2021-03-03 | ||
| US202163165457P | 2021-03-24 | 2021-03-24 | |
| US63/165,457 | 2021-03-24 | ||
| PCT/US2022/018672 WO2022187463A1 (en) | 2021-03-03 | 2022-03-03 | Methods for treating familial chylomicronemia syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024508334A JP2024508334A (ja) | 2024-02-26 |
| JP2024508334A5 true JP2024508334A5 (https=) | 2025-03-06 |
Family
ID=80819670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553354A Pending JP2024508334A (ja) | 2021-03-03 | 2022-03-03 | 家族性高カイロミクロン血症症候群を治療するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240165093A1 (https=) |
| EP (1) | EP4301361A1 (https=) |
| JP (1) | JP2024508334A (https=) |
| KR (1) | KR20230153375A (https=) |
| AU (1) | AU2022231007A1 (https=) |
| BR (1) | BR112023016943A2 (https=) |
| CA (1) | CA3208189A1 (https=) |
| IL (1) | IL305191A (https=) |
| MX (1) | MX2023010297A (https=) |
| WO (1) | WO2022187463A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3186856A1 (en) | 2020-07-29 | 2022-02-03 | Ruth NALLEN | Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| KR101494067B1 (ko) | 2004-03-05 | 2015-02-16 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법 |
| BR102015025502B1 (pt) | 2015-04-30 | 2022-06-21 | Aegerion Pharmaceuticals, Inc | Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição |
-
2022
- 2022-03-03 CA CA3208189A patent/CA3208189A1/en active Pending
- 2022-03-03 AU AU2022231007A patent/AU2022231007A1/en active Pending
- 2022-03-03 MX MX2023010297A patent/MX2023010297A/es unknown
- 2022-03-03 BR BR112023016943A patent/BR112023016943A2/pt unknown
- 2022-03-03 JP JP2023553354A patent/JP2024508334A/ja active Pending
- 2022-03-03 IL IL305191A patent/IL305191A/en unknown
- 2022-03-03 EP EP22711788.4A patent/EP4301361A1/en active Pending
- 2022-03-03 US US18/548,798 patent/US20240165093A1/en active Pending
- 2022-03-03 WO PCT/US2022/018672 patent/WO2022187463A1/en not_active Ceased
- 2022-03-03 KR KR1020237028890A patent/KR20230153375A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11185519B2 (en) | Methods of treatment of cholestatic diseases | |
| CA3043284C (en) | Treatment for fibrosis | |
| US10980810B2 (en) | Combination therapy comprising an ACC inhibitor | |
| Cefalù et al. | Efficacy and safety of lomitapide in familial chylomicronaemia syndrome | |
| EA020849B1 (ru) | Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени | |
| WO2015105757A1 (en) | Dimethyl fumarate for treating multiple sclerosis | |
| US20190175619A1 (en) | Treatment of fibrosis, and inhibition of fibrosis in non-alcoholic fatty liver disease patients | |
| US20200297672A1 (en) | Methods of treatment of cholestatic diseases | |
| JP2023501457A5 (https=) | ||
| Han et al. | Targeting FABP4 to inhibit AGEs‐RAGE/NF‐κB signalling effectively ameliorates nucleus pulposus dysfunction and angiogenesis in obesity‐related intervertebral disc degeneration | |
| JP2024508334A5 (https=) | ||
| Won et al. | Balancing low-density lipoprotein cholesterol reduction and hepatotoxicity with lomitapide mesylate and mipomersen in patients with homozygous familial hypercholesterolemia | |
| WO2022249071A1 (en) | Pemafibrate and/or tofogliflozin for use in treating liver disease | |
| RU2023125042A (ru) | Способы лечения синдрома семейной хиломикронемии | |
| JP2024508334A (ja) | 家族性高カイロミクロン血症症候群を治療するための方法 | |
| CN112203658A (zh) | 包含卓匹非索和塞尼韦洛的组合 | |
| US20220347190A1 (en) | Treatment comprising fxr agonists | |
| CN112823007A (zh) | 用巴瑞替尼治疗原发性胆汁性胆管炎和原发性硬化性胆管炎 | |
| US20250332176A1 (en) | Treatment for fibrosis and inhibition of fibrosis | |
| KR101647348B1 (ko) | Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물 | |
| CN116019914B (zh) | Gpr180抑制剂在制备改善糖或脂代谢药物中的用途 | |
| CN110099686B (zh) | 非酒精性脂肪性肝病的治疗 | |
| US20220362263A1 (en) | Treatment for fibrosis and inhibition of fibrosis | |
| AU2019376907B2 (en) | Treatment and inhibition of fibrosis in non-alcoholic fatty liver disease patients | |
| WO2026092666A1 (zh) | 一种化合物或其药学上可接受的盐在治疗糖代谢型疾病中的应用 |